CD44s在非小细胞肺癌中的表达研究

Expression of CD44s in non small cell lung cancer

目的 探讨标准型 Ｃ Ｄ４４（ Ｃ Ｄ４４ｓ） 在非小细胞肺癌（ Ｎ Ｓ Ｃ Ｌ Ｃ） 中的临床应用价值。方法 用免疫组织化学方法检测 Ｎ Ｓ Ｃ Ｌ Ｃ１８０ 例和淋巴结 Ｎ Ｓ Ｃ Ｌ Ｃ 转移癌５１ 例的石蜡标本 Ｃ Ｄ４４ｓ 表达强度，并对１８０ 例 Ｎ Ｓ Ｃ Ｌ Ｃ 的术中情况进行记录，对其中１４１ 例病人进行随访分析。结果 Ｃ Ｄ４４ｓ 强表达的 Ｎ Ｓ Ｃ Ｌ Ｃ 多为Ⅰ期，术中淋巴结转移率及４ 年转移率较低，病人生存期较长；淋巴结 Ｎ Ｓ Ｃ Ｌ Ｃ 转移癌的 Ｃ Ｄ４４ｓ 表达率较原发灶低。结论 Ｃ Ｄ４４ｓ 强表达的 Ｎ Ｓ Ｃ Ｌ Ｃ 病人多为早期，发生转移可能性较少，生存期较长，可能是 Ｎ Ｓ Ｃ Ｌ Ｃ 一个预后良好的指标。

Objective To investigate the clinical value of standard CD44 (CD44s) in non small cell lung cancer (NSCLC). Methods The intensity of CD44s expression in 180 paraffin embedded NSCLC specimens in group A and 51 paraffin embedded NSCLC′s lymphatic metastasis specimens in group B were detected by using immunohistochemical staining method. Tumor records during operation of 180 patients in group A were documented and 141 patients in group A were followed up. Results Most of the NSCLC of CD44s strong expression belonged to stage I, its lymphatic metastatic and 4 year metastatic rate were relatively low and the patients had a longer survival time. The rate of CD44s expression in NSCLC′s metastatic lymph nodes was less than that in primary lesion. Conclusion Most of the patients with CD44s strong expression are classified into early stage of NSCLC and have lower rate of metastasis with a longer survival time. CD44s strong expression may be a better prognostic marker of NSCLC.